Ambrx adds Chris Nolet to its Board of Directors as Chair of the Audit Committee

– USA, CA –  Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to its Board of Directors.

Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry and has assumed the role of Chair of Ambrx’s Audit Committee.

“We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said CEO, Dr. Feng Tian. “His experience in helping transition clinical stage companies into commercially integrated pharmaceutical companies should prove invaluable to Ambrx. As Chair of the Audit Committee, he will provide the accounting and financial oversight to support Ambrx through the next stages of the company’s growth. I am confident that Chris will prove to be an indispensable board member and look forward to benefiting from his counsel in the years ahead.”

About Chris Nolet

Mr. Nolet currently serves on the Boards of Viela Bio (NASDAQ: VIE), where he is Chair of the Audit Committee, PolarityTE, Inc. (Nasdaq: PTE), where he is Chair of the Audit Committee, and Revance Therapeutics (NASDAQ: RVNC), where he is also Chair of the Audit Committee. Also, Mr. Nolet serves on both the Executive Committee and Finance Committee of the California Life Sciences Association and is a former member of the Finance & Investment Committee and Emerging Companies Section of the Biotechnology Innovation Organization.

Mr. Nolet is the former West Region Life Sciences Industry Leader & Partner at EY, retiring in June of 2019 after more than 38 years in the profession. In addition to serving clients, his responsibilities included leading West Region EY Life Sciences Industry Group, and serving as a member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for EY Life Sciences practice worldwide. Before joining EY, Mr. Nolet was​ ​a partner at PricewaterhouseCoopers where he led the life sciences practice in the western U.S.

“I am very pleased to join Ambrx’s Board at such a pivotal time in the company’s history, and to help the development of Ambrx’ Engineered Precision Biologics, which could dramatically improve the treatment outcomes for a variety of cancer patients,” said Mr. Nolet. “Ambrx recently completed a $200 million private financing round that included some of the world’s leading healthcare investors. Also, Ambrx’s lead development candidate, ARX788, has generated promising clinical data, and received Fast Track Designation from the FDA as a potential monotherapy for the treatment of metastatic HER2-positive breast cancer patients.”

He holds a B.S. in accounting from San Diego State University and ​is​ a Certified Public Accountant in California.

About Ambrx

Ambrx is a clinical-stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics. These include next-generation antibody-drug conjugates, bispecific, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety, and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. Also, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.

For more information: http://ambrx.com/